https://orcid.org/0000-0003-1353-045X
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gabriela Toutin Dias & Michael E Schatman. (2022) Pain Management Providers in the Era of COVID-19: Who is Taking Care of Those Who Provide Care?. Journal of Pain Research 15, pages 67-70.
Read now
Read now
Bo Pang, Yuan Zhang, Yu Zhou, Zhi-fei Liu, Xiao-jun Liu & Xue-song Feng. (2022) Recent Update on Pretreatment and Analysis Methods of Buprenorphine in Different Matrix. Critical Reviews in Analytical Chemistry 0:0, pages 1-30.
Read now
Read now
Cynthia Zubritsky, Anne C. Futterer, Hilary Cantiello, Emeric Quade, Devin Yastro, Molly Candon & David Horowitz. Emergency engagement for opioid use disorder: subjective measures of health and wellness following a warm hand-off in emergency departments. Journal of Substance Use 0:0, pages 1-7.
Read now
Read now
Articles from other publishers (8)
Charlotte S. Johnstone, Cherry E. Koh, Gregory J. Britton, Michael J. Solomon & Andrew J. McLachlan. (2022) Implementation of a peri‐operative pain‐management algorithm reduces the use of opioid analgesia following pelvic exenteration surgery. Colorectal Disease 25:4, pages 631-639.
Crossref
Crossref
Kyle J. NealeMelissa B. WeimerMellar P. DavisKatie Fitzgerald JonesJustin G. KullgrenSachin S. KaleJulie ChildersKathleen Broglio, Jessica S. MerlinSarah PeckSheria Y. FrancisJacqueline BangoChristopher A. JonesZachary SagerJ. Janet Ho. (2023) Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine. Journal of Palliative Medicine 26:1, pages 120-130.
Crossref
Crossref
Alba Vidal-Torres, Begoña Fernández-Pastor, Mónica García, Eva Ayet, Anna Cabot, Javier Burgueño, Xavier Monroy, Bertrand Aubel, Xavier Codony, Luz Romero, Rosalía Pascual, Maria Teresa Serafini, Gregorio Encina, Carmen Almansa, Daniel Zamanillo, Manuel Merlos & José Miguel Vela. (2023) Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids. Acta Pharmaceutica Sinica B 13:1, pages 82-99.
Crossref
Crossref
Todd A. Miano, Lei Wang, Charles E. Leonard, Colleen M. Brensinger, Emily K. Acton, Ghadeer K. Dawwas, Warren B. Bilker, Samantha E. Soprano, Thanh Phuong Pham Nguyen, George Woody, Elmer Yu, Mark Neuman, Lang Li & Sean Hennessy. (2022) Identifying Clinically Relevant Drug–Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. Clinical Pharmacology & Therapeutics 112:5, pages 1120-1129.
Crossref
Crossref
Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M. Kaye & Alan D Kaye. (2022) Buprenorphine and its formulations: a comprehensive review. Health Psychology Research 10:3.
Crossref
Crossref
Flaminia Coluzzi, Laura Rullo, Maria Sole Scerpa, Loredana Maria Losapio, Monica Rocco, Domenico Billeci, Sanzio Candeletti & Patrizia Romualdi. (2022) Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 36:6, pages 617-632.
Crossref
Crossref
Tim Quach, Luojuan Hu, Sifei Han, Shea F. Lim, Danielle Senyschyn, Preeti Yadav, Natalie L. Trevaskis, Jamie S. Simpson & Christopher J. H. Porter. (2022) Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport. Frontiers in Pharmacology 13.
Crossref
Crossref
Isaac A. Adedara, Fabiano V. Costa, Eduarda Biasuz, Julia Canzian, Ebenezer O. Farombi & Denis B. Rosemberg. (2022) Influence of acid-sensing ion channel blocker on behavioral responses in a zebrafish model of acute visceral pain. Behavioural Brain Research 416, pages 113565.
Crossref
Crossref